RB inhibits NSCLC progression and sensitizes cells to CDDP by directly targeting SRC to inactivate the PI3K/AKT pathway. These findings identify a novel mechanism of RB against NSCLC and suggest its potential as a therapeutic strategy.
Building similarity graph...
Analyzing shared references across papers
Loading...
Xi Chen
South China Agricultural University
Jihong Hao
Zhengzhou University
Chenfeng Guo
Zhengzhou University
Pharmaceutical Biology
Zhengzhou University
Henan Provincial People's Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Chen et al. (Thu,) studied this question.
synapsesocial.com/papers/69bf86ecf665edcd009e901f — DOI: https://doi.org/10.1080/13880209.2026.2641262
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: